In a 19‑year‑old female with a pruritic, painful annular rash involving both breasts and the right forearm diagnosed as tinea corporis and treated with oral terbinafine 250 mg daily for one week, the rash has now spread—what is the appropriate next step in management?

Discontinue Terbinafine and Switch to Itraconazole

In this 19-year-old with spreading tinea corporis after one week of terbinafine 250 mg daily, you should stop terbinafine immediately and switch to itraconazole 200 mg daily for 4 weeks. The spreading rash after one week of treatment indicates treatment failure, and the clinical presentation with multifocal involvement (bilateral breasts and right arm) suggests this may be a Microsporum species infection, for which terbinafine has poor efficacy 1.

Why Terbinafine is Failing

The British Association of Dermatologists guidelines explicitly state that terbinafine has much higher efficacy against Trichophyton species than Microsporum 1. The patient's exposure history is critical here: she moved into an apartment previously occupied by a cat, and she has a known cat allergy. Microsporum canis is the classic zoophilic dermatophyte transmitted from cats 2, and terbinafine's minimum inhibitory concentration for M. canis can exceed the maximum concentration achieved in tissue, leading to treatment failures 1.

Additionally, the guidelines note that at higher doses, terbinafine is more effective against Trichophyton, but prolonging treatment does not improve efficacy for Microsporum infections 1. This means continuing or increasing terbinafine is futile if this is M. canis.

The Correct Next Step

Immediate Actions:

1. Stop terbinafine now – continuing ineffective therapy allows disease progression and increases patient morbidity through persistent symptoms

2. Obtain proper diagnostic specimens before starting new therapy:

   • KOH preparation and fungal culture from active border of lesions
   • Request species identification (not just "dermatophyte positive")
   • Consider molecular testing (ITS sequencing) if available, especially given emerging resistant strains 3, 4

3. Start itraconazole 200 mg daily for 4 weeks 1

Why Itraconazole is the Right Choice:

The guidelines are clear: itraconazole is safe, effective, and has activity against both Trichophyton AND Microsporum species 1. This makes it the ideal second-line agent when the causative organism is unknown or when Microsporum is suspected. The recommended dosing is 200 mg daily (or 5 mg/kg/day) for 4 weeks 1.

Recent evidence supports this approach: a 2026 case report of T. indotineae (an emerging terbinafine-resistant species) showed successful treatment with itraconazole 200 mg daily for 8 weeks 3. Another 2023 case of recurrent, terbinafine-resistant T. rubrum required long-term itraconazole therapy 5.

Critical Considerations for This Patient

The Hepatotoxicity Concern:

The FDA label warns that terbinafine can cause liver failure requiring transplant or death 6. This patient is already on multiple medications that stress the liver (omeprazole, Pepcid, Carafate for apparent GI issues). The medical decision-making notes state she declined baseline liver function testing before starting terbinafine 6.

Before starting itraconazole, you MUST obtain baseline liver function tests (ALT, AST) 6. The patient cannot refuse this time – explain that continuing antifungal therapy without monitoring could result in severe liver injury.

Rule Out Emerging Resistant Strains:

The spreading rash despite treatment raises concern for:

• Terbinafine-resistant dermatophytes (33% of recent isolates show high terbinafine MICs) 4
• Emerging species like T. indotineae (now reported in Virginia and spreading across the US) 3
• These infections "generally do not improve with first-line topical or oral antifungals" 7

Address the Infection Source:

The patient's dog has a "scaling rash" – this animal likely harbors M. canis and will continue reinfecting the patient unless treated. Coordinate with veterinary care for the dog and ensure all household contacts (including her fiancé, who may be asymptomatic) are evaluated.

Treatment Algorithm Going Forward

Week 1-4: Itraconazole 200 mg daily

• Monitor LFTs at baseline, week 2, and week 4
• Discontinue if ALT/AST >3x upper limit of normal 6
• Ensure strict compliance (take with food to enhance absorption)

Week 4 Assessment:

• If clinical improvement but culture still positive: continue itraconazole another 2-4 weeks 1
• If no clinical improvement: consider dermatology referral for alternative agents (fluconazole, voriconazole) or combination therapy 1
• If complete resolution: continue until mycological cure confirmed 1

Adjunctive Measures:

• Continue topical antifungal (switch from mupirocin to an azole like clotrimazole or miconazole) 5
• Strict hygiene: wash all clothing, bras, bedding, towels after each use 1
• Avoid sharing personal items
• Keep skin clean and dry (especially under breasts where she reports sweating)

Common Pitfalls to Avoid

1. Don't just increase the terbinafine dose – a 2023 study showed 500 mg terbinafine was no better than 250 mg for tinea corporis/cruris, with poor cure rates in both groups (20% vs 33%) 8

2. Don't continue terbinafine "a bit longer" – the guidelines state if there's no initial clinical improvement, proceed to second-line therapy immediately 1

3. Don't use topical steroids – the plan correctly notes to avoid these on fungal lesions, as they worsen infection and can create "tinea incognito"

4. Don't ignore the breast imaging – while the rash is likely purely infectious, the bilateral fibrotic breast tissue and persistent skin changes warrant the ordered ultrasound to exclude inflammatory breast conditions

The patient should return in 2 weeks for clinical assessment and repeat visit at 4 weeks with repeat fungal culture to document mycological cure. If the rash continues spreading on itraconazole, urgent dermatology referral is mandatory for consideration of resistant organisms requiring specialized testing and alternative antifungal regimens 5, 3.